These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 8518678)

  • 1. Risk assessment adjusted for gestational age in maternal serum screening for Down's syndrome.
    Gardosi J; Mongelli M
    BMJ; 1993 Jun; 306(6891):1509-11. PubMed ID: 8518678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maternal serum screening for Down's syndrome: the effect of routine ultrasound scan determination of gestational age and adjustment for maternal weight.
    Wald NJ; Cuckle HS; Densem JW; Kennard A; Smith D
    Br J Obstet Gynaecol; 1992 Feb; 99(2):144-9. PubMed ID: 1372820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prenatal screening for Down's syndrome with use of maternal serum markers.
    Haddow JE; Palomaki GE; Knight GJ; Williams J; Pulkkinen A; Canick JA; Saller DN; Bowers GB
    N Engl J Med; 1992 Aug; 327(9):588-93. PubMed ID: 1379344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antenatal maternal serum screening for Down's syndrome: results of a demonstration project.
    Wald NJ; Kennard A; Densem JW; Cuckle HS; Chard T; Butler L
    BMJ; 1992 Aug; 305(6850):391-4. PubMed ID: 1382768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective study of prenatal screening for Down's syndrome with free beta human chorionic gonadotrophin.
    Spencer K; Carpenter P
    BMJ; 1993 Sep; 307(6907):764-9. PubMed ID: 7693095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biparietal diameter and crown-rump length in fetuses with Down's syndrome: implications for antenatal serum screening for Down's syndrome.
    Wald NJ; Smith D; Kennard A; Palomaki GE; Salonen R; Holzgreve W; Pejtsik B; Coombes EJ; Mancini G; MacRae AR
    Br J Obstet Gynaecol; 1993 May; 100(5):430-5. PubMed ID: 8518242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementation of an antenatal serum screening programme for Down's syndrome in two districts (Brighton and Eastbourne). The Brighton and Eastbourne Down's Syndrome Screening Group.
    Piggott M; Wilkinson P; Bennett J
    J Med Screen; 1994 Jan; 1(1):45-9. PubMed ID: 8790485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prenatal screening for fetal aneuploidy in singleton pregnancies.
    Chitayat D; Langlois S; Douglas Wilson R; ;
    J Obstet Gynaecol Can; 2011 Jul; 33(7):736-750. PubMed ID: 21749752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antenatal screening for Down's syndrome.
    Wald NJ; Kennard A; Hackshaw A; McGuire A
    J Med Screen; 1997; 4(4):181-246. PubMed ID: 9494915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for fetal Down's syndrome in pregnancy by measuring maternal serum alpha-fetoprotein levels.
    DiMaio MS; Baumgarten A; Greenstein RM; Saal HM; Mahoney MJ
    N Engl J Med; 1987 Aug; 317(6):342-6. PubMed ID: 2439909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second trimester screening for Down's syndrome using maternal serum dimeric inhibin A.
    Haddow JE; Palomaki GE; Knight GJ; Foster DL; Neveux LM
    J Med Screen; 1998; 5(3):115-9. PubMed ID: 9795869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective audit of different antenatal screening policies for Down's syndrome in eight district general hospitals in one health region.
    Wellesley D; Boyle T; Barber J; Howe DT
    BMJ; 2002 Jul; 325(7354):15. PubMed ID: 12098722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SURUSS in perspective.
    Wald NJ; Rodeck C; Hackshaw AK; Rudnicka A
    Semin Perinatol; 2005 Aug; 29(4):225-35. PubMed ID: 16104673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of a regional screening programme using maternal serum alpha fetoprotein (AFP) and human chorionic gonadotrophin (hCG) on the birth incidence of Down's syndrome in the west of Scotland.
    Crossley JA; Aitken DA; Berry E; Connor JM
    J Med Screen; 1994 Jul; 1(3):180-3. PubMed ID: 8790513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Screening by maternal serum markers for Down's syndrome].
    Liu JT; Hao N; Sun NH; Wang FY; Xu YH; Gai MY; Bian XM; Yang JQ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Apr; 25(2):156-9. PubMed ID: 12905710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of routine screening for Down's syndrome on the significance of isolated fetal hydronephrosis.
    Thompson MO; Thilaganathan B
    Br J Obstet Gynaecol; 1998 Aug; 105(8):860-4. PubMed ID: 9746378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reducing the need for amniocentesis in women 35 years of age or older with serum markers for screening.
    Haddow JE; Palomaki GE; Knight GJ; Cunningham GC; Lustig LS; Boyd PA
    N Engl J Med; 1994 Apr; 330(16):1114-8. PubMed ID: 7510852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prenatal screening for Down's syndrome using inhibin-A as a serum marker.
    Wald NJ; Densem JW; George L; Muttukrishna S; Knight PG
    Prenat Diagn; 1996 Feb; 16(2):143-53. PubMed ID: 8650125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prenatal biochemical screening for Down's syndrome and neural tube defects.
    Wald NJ; Kennard A
    Curr Opin Obstet Gynecol; 1992 Apr; 4(2):302-7. PubMed ID: 1373963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SURUSS in perspective.
    Wald NJ; Rodeck C; Hackshaw AK; Rudnicka A
    BJOG; 2004 Jun; 111(6):521-31. PubMed ID: 15198778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.